产肠毒素大肠杆菌菌毛黏附素经皮免疫首次人体试验的安全性与免疫原性
疫苗耐受良好,局部反应轻微;抗毒素血清IgA/IgG应答率在接受LTR(192G)组为75%至100%,而dscCfaE应答频率中等。
要点
- 经皮递送dscCfaE联合LTR(192G)疫苗耐受良好,局部反应轻微。
- 接受LTR(192G)组抗毒素血清IgA/IgG应答率为75%至100%。
- dscCfaE特异性抗体分泌细胞应答在所有剂量组均被诱导但普遍较低。
核心结论
- 经皮递送dscCfaE联合LTR(192G)的3剂方案安全耐受,抗毒素应答率高,但抗dscCfaE应答中等。
研究设计与样本
- 疫苗经皮贴片给药,3剂方案(第0、21、42天),与LTR(192G)联合给药;50 µg剂量组中10名受试者仅接受dscCfaE无LTR(192G)。
主要发现
- 疫苗耐受良好,局部反应为轻度红斑丘疹和瘙痒,未接受LTR(192G)组反应更少且更轻。
- 抗毒素血清IgA/IgG应答率在接受LTR(192G)组为75%至100%。
- dscCfaE应答频率中等;抗原特异性抗体分泌细胞应答在所有剂量组均被诱导但普遍较低。
临床怎么用
- 后续研究需优化构建体和递送途径,并在ETEC攻击试验中评估效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea among travelers and pediatric populations worldwide. The tip-localized adhesin of colonization factor antigen (CFA)/I fimbriae was engineered as a donor strand complemented variant (dscCfaE) and delivered via transcutaneous immunization. Preclinical vaccine testing demonstrated safety, immunogenicity and efficacy. A series of open-label dose-escalating phase 1 studies evaluated a 3-dose (days 0, 21, 42) regimen via a transcutaneous skin patch. A total of forty-six subjects were enrolled into one of four vaccine dose levels (10, 50, 250, or 1250 µg) co-administered with single-mutant heat-labile enterotoxin (LTR(192G)). At the 50 µg dose level, ten subjects received the dscCfaE vaccine without LT(R192G). The vaccine was well tolerated with mild local vaccine site reactions characterized by an erythematous papular rash and pruritus, which were less frequent and reactive in the group not receiving LT(R192G). The frequency of responses to dscCfaE were moderate, whereas anti-toxin responses (serum IgA/IgG) ranged from 75 to 100% across groups that received LT(R192G). Antigen-specific antibody-secreting cell responses were elicited at all dose levels, but were generally low. Follow-on studies will optimize construct and route of delivery and assess efficacy in an ETEC challenge study.
引用
- Riddle MS, Maciel M, Porter CK, et al. A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. Vaccine. 2020. PMID: 32978003. doi:10.1016/j.vaccine.2020.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。